S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
The #1 Crypto for 2024 (Ad)
Closing prices for crude oil, gold and other commodities
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Top 5 Tech Stocks to Buy for 2024 (Ad)
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
The #1 Crypto for 2024 (Ad)
Closing prices for crude oil, gold and other commodities
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Top 5 Tech Stocks to Buy for 2024 (Ad)
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
The #1 Crypto for 2024 (Ad)
Closing prices for crude oil, gold and other commodities
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Top 5 Tech Stocks to Buy for 2024 (Ad)
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
The #1 Crypto for 2024 (Ad)
Closing prices for crude oil, gold and other commodities
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Top 5 Tech Stocks to Buy for 2024 (Ad)
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
Free Trial

Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Resverlogix Corp. stock logo
RVX
Resverlogix
C$0.06
C$0.06
C$0.05
▼
C$0.17
C$14.97M0.7838,494 shs52,090 shs
These 7 Stocks Will Be Magnificent in 2024 Cover
These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Resverlogix Corp. stock logo
RVX
Resverlogix
0.00%0.00%-8.33%-15.38%-66.67%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AC$0.00 per share132.50C($0.26) per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Resverlogix Corp. stock logo
RVX
Resverlogix
-C$12.82M-C$0.05N/A∞N/AN/AN/A-37.10%5/9/2024 (Estimated)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A
0.11
0.04

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A

Insider Ownership

CompanyInsider Ownership
Resverlogix Corp. stock logo
RVX
Resverlogix
43.19%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Resverlogix Corp. stock logo
RVX
Resverlogix
19272.17 millionN/ANot Optionable

RVX Headlines

SourceHeadline
Resverlogix Announces Change to Its Board of DirectorsResverlogix Announces Change to Its Board of Directors
finance.yahoo.com - February 21 at 8:02 PM
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalones Potential Therapeutic BenefitsResverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
finance.yahoo.com - January 11 at 10:03 AM
Closing Bell: Resverlogix Corp flat on Tuesday (RVX)Closing Bell: Resverlogix Corp flat on Tuesday (RVX)
theglobeandmail.com - January 4 at 6:16 PM
Resverlogix Corp. (RVX) Earnings Dates & ReportsResverlogix Corp. (RVX) Earnings Dates & Reports
investing.com - December 19 at 7:28 PM
Resverlogix Corp RVXCFResverlogix Corp RVXCF
morningstar.com - November 18 at 5:49 PM
Resverlogix Corp RVXResverlogix Corp RVX
morningstar.com - November 1 at 11:18 AM
Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)
theglobeandmail.com - October 18 at 7:46 AM
Resverlogix Corp.: Resverlogix Publishes on Apabetalones Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophyResverlogix Corp.: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
finanznachrichten.de - October 4 at 10:11 AM
Resverlogix Publishes on Apabetalones Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophyResverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
finance.yahoo.com - October 4 at 10:11 AM
Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsightAtherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsight
finance.yahoo.com - September 26 at 8:50 PM
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 DiabetesResverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
finance.yahoo.com - August 29 at 10:13 AM
Closing Bell: Resverlogix Corp up on Wednesday (RVX)Closing Bell: Resverlogix Corp up on Wednesday (RVX)
theglobeandmail.com - August 24 at 3:35 PM
Closing Bell: Resverlogix Corp flat on Monday (RVX)Closing Bell: Resverlogix Corp flat on Monday (RVX)
theglobeandmail.com - August 14 at 10:02 PM
Closing Bell: Resverlogix Corp Warrants down on Wednesday (RVX-WT-A)Closing Bell: Resverlogix Corp Warrants down on Wednesday (RVX-WT-A)
theglobeandmail.com - July 12 at 7:21 AM
Resverlogix Announces Warrant Repricing and One-Year ExtensionResverlogix Announces Warrant Repricing and One-Year Extension
finance.yahoo.com - June 29 at 11:09 PM
Resverlogix Corp.: Resverlogix Announces Voting Results from the 2023 Meeting of ShareholdersResverlogix Corp.: Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders
finanznachrichten.de - June 20 at 7:31 PM
Resverlogix Announces Voting Results from the 2023 Meeting of ShareholdersResverlogix Announces Voting Results from the 2023 Meeting of Shareholders
finance.yahoo.com - June 20 at 7:31 PM
Resverlogix Announces New Insights into the Mechanism of Apabetalones Cardioprotective Benefit in Chronic Kidney Disease PatientsResverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
finance.yahoo.com - June 12 at 6:42 PM
Canadian Investment Regulatory Organization Trading Halt - RVX.WT.ACanadian Investment Regulatory Organization Trading Halt - RVX.WT.A
finance.yahoo.com - June 7 at 1:32 PM
Closing Bell: Resverlogix Corp Warrants down on Friday (RVX-WT-A)Closing Bell: Resverlogix Corp Warrants down on Friday (RVX-WT-A)
theglobeandmail.com - June 6 at 10:49 AM
Closing Bell: Resverlogix Corp Warrants down on Tuesday (RVX-WT-A)Closing Bell: Resverlogix Corp Warrants down on Tuesday (RVX-WT-A)
theglobeandmail.com - May 25 at 12:52 AM
CBOE RUSSELL 2000 VOLATILITY IN (^RVX)CBOE RUSSELL 2000 VOLATILITY IN (^RVX)
finance.yahoo.com - May 18 at 12:38 AM
Bromodomain Containing Protein 2 Market is Likely to Upsurge at ... - StreetBuzzBromodomain Containing Protein 2 Market is Likely to Upsurge at ... - StreetBuzz
news.google.com - May 13 at 3:47 PM
Resverlogix : MD&A Q1 2023 - Marketscreener.comResverlogix : MD&A Q1 2023 - Marketscreener.com
news.google.com - May 12 at 3:50 PM

Media Sentiment Over Time

Company Descriptions

Resverlogix logo

Resverlogix

TSE:RVX
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.